Should we continue to use renin-angiotensin-aldosterone system blockers in patients with COVID-19?
Sidar CopurAsiye KanbayMehmet KanbayPublished in: Clinical kidney journal (2022)
Patients with chronic kidney disease, chronic heart failure and hypertension have an increased risk of coronavirus disease 2019 (COVID-19)-related death. Renin-angiotensin-aldosterone system (RAS) blockers are commonly prescribed to decrease morbidity and mortality in these conditions. Following the pre-clinical demonstration of COVID-19 viral entry into cells via angiotensin-converting enzyme-2, the use of RAS blockers was questioned in infected individuals. Theodorakopoulou et al. extensively review the pathophysiology behind that hypothesis and observational or clinical trials on RAS blockers and COVID-19. Despite being a scientific hot spot of an ongoing debate, discontinuation of RAS blockers is not associated with improved clinical outcomes in COVID-19 and may have potential harmful effects, including exacerbation of the underlying disease.
Keyphrases
- angiotensin converting enzyme
- coronavirus disease
- angiotensin ii
- sars cov
- respiratory syndrome coronavirus
- wild type
- clinical trial
- blood pressure
- chronic obstructive pulmonary disease
- induced apoptosis
- randomized controlled trial
- multidrug resistant
- cross sectional
- oxidative stress
- risk assessment
- mechanical ventilation
- signaling pathway
- study protocol
- pi k akt